NeuroPace falls after setback in trial for neuromodulation system
Source: SeekingAlpha
2025-05-27 09:04:32 ET
More on NeuroPace
- NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript
- NeuroPace, Inc. 2025 Q1 - Results - Earnings Call Presentation
- NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript
- NeuroPace reports Q1 results; raises FY25 outlook
- NeuroPace outlines 20%+ CAGR through 2027 as RNS business momentum accelerates
Read the full article on Seeking Alpha
For further details see:
NeuroPace falls after setback in trial for neuromodulation system
Neuropace Inc.
NASDAQ: NPCE
NPCE Trading
2.58% G/L:
$14.30 Last:
89,607 Volume:
$14.22 Open:
NPCE Latest News
March 03, 2026 04:05:00 pm
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
NPCE Stock Data
$508,942,176
26,479,649
0.24%
22
N/A
Medical Equipment & Supplies
Healthcare
US
Mountain View
